The #1 chase in 2026 Bowman. BCP-1 PSA 10 math, injury impact, exact re-entry window, and every parallel ranked by print run vs. upside. Son of Matt Holliday — the pedigree is real.
Three things converge: elite pedigree, elite tool set, and an injury discount that created a buying window. Here's what you need to know before touching a single card.
Ethan Holliday is the son of Matt Holliday, a 7× All-Star who slugged .492 for his career and won a World Series ring. Pedigree cards carry a collector premium that goes beyond on-field production — they create multi-generational narratives that sustain long-term demand. His older brother Jackson Holliday's BCP-1 trajectory is the direct comp: from sub-$100 raw to four-figure PSA 10 territory inside 18 months of a hot debut.
Injuries create fear. Fear creates discount. Here's exactly what happened and what the market did in response.
Track Holliday's wrist health via beat reporters (not just official team statements). The two clearest buy signals: (1) 2-week stretch with exit velocities above 95 mph on pulled balls, confirming full wrist engagement; (2) promotion to AA/AAA, which historically triggers 40–80% price jumps on top-prospect cards within 30 days.
Four plays, one clear hierarchy. Prices from eBay completed and recently sold listings, June 2026.
The highest ROI play on the board right now. Raw gem candidates are cards that grade out at PSA 10 — centering 55/45 or better, four sharp corners, no surface scratches visible under 10× loupe. Buying gem candidates at $75–$95 and sending to PSA for a 10 grade unlocks $380+ in value, net of ~$30 grading cost. That's a $265+ gross return per card on a $30 grading investment.
The key skill here is pulling true gem candidates. Look for: center-focused print (the Bowman Chrome centering issue affects roughly 30–40% of pulls), no chipping on the black borders, and surfaces that stay clean under direct light at multiple angles. Reject any card with a visible print line or soft corner under loupe — PSA will catch it.
The auto is the generational card. Holliday's on-card autograph is large, consistent, and clear — a good auto for grading. PSA 10 auto BCP-1 cards for top prospects with comparable pedigree (Jackson Holliday, Druw Jones) have cleared $2,500+ at their peaks. Ethan's auto PSA 10 pop is extremely low right now — this is an asymmetric bet.
The math: pay $400–$550 raw, grade at $30–$50, receive PSA 10, comp at $1,800+. That's a $1,250+ gross return if you pull a true 10. Note: Holliday's auto quality is consistent but you'll see some sloppier examples — inspect every single card before buying. Reject any ink skip, any letter that looks incomplete at the tail.
Buying a pre-graded PSA 10 eliminates grading risk and turnaround time. At ~$380, you're paying a premium over the raw gem candidate play, but you're guaranteed the result. Best for buyers who want liquid, marketable exposure to a Holliday breakout without the grading lottery. PSA 10 BCP-1 slabs trade easily and are the most common format for resale.
If Holliday hits AAA before year-end, $600–$700 on a PSA 10 BCP-1 is a reasonable Q4 target. That's a 60–85% return from current comps. Not as explosive as the raw gem play, but far more predictable.
Numbered parallels offer lower-pop-count exposure with collector scarcity premiums. The Blue /150 is the entry-level numbered parallel and the most liquid — easiest to buy, easiest to sell. The Purple /75 sits at the sweet spot of scarcity vs. affordability. The Gold /50 and rarer are for high-conviction holders only — illiquid but explosive on a breakout.
Important note: parallels do not necessarily grade at the same rate as base BCP-1. Bowman Chrome parallels often have different centering characteristics. Inspect centering on every numbered card — a /50 with poor centering is worth significantly less than a /50 gem candidate.
Here's exactly what each grade is worth right now and what the grade-up math looks like at current PSA turnaround costs. All figures from eBay completed sales, June 2026.
| Grade | Market Value | vs. Raw | Grade Cost | Net Return | Verdict |
|---|---|---|---|---|---|
| Raw (Poor) | $30–$50 | — | — | — | Don't buy. Not gradeable. |
| Raw (Mid) | $55–$75 | — | $30 | Grade only if PSA 8/9 candidate | Skip unless obvious 9+ |
| Raw (Gem Cand.) | $75–$95 | — | $30 | +$255 net (PSA 10 target) | Best ROI entry |
| PSA 7 | $55–$80 | 0.7× | — | — | No. Below raw in premium |
| PSA 8 | $100–$140 | 1.3× | — | — | Skip. Weak premium vs. 10 |
| PSA 9 | $160–$220 | 2.1× | — | — | Hold if you have one. Don't buy. |
| PSA 10 ⭐ | ~$380 | 4.5× | $30 | +$265 gross | The only grade worth buying |
| PSA 10 Auto | $1,800+ | — | $50 | +$1,250+ gross | Highest asymmetric bet |
On BCP-1 Holliday, the entire value thesis concentrates at PSA 10. PSA 8 and 9 carry marginal premium that doesn't justify buying over raw. If you're grading, you're grading for 10 or not grading at all. Any raw card that isn't a clear gem candidate (55/45+ centering, four sharp corners, pristine surfaces under loupe) should be sold raw or held raw — not graded. Grading a PSA 8 candidate is just paying $30 to discover a card worth less than you paid for it.
Every parallel ranked by print run and estimated current market value. Rarer = higher ceiling, lower liquidity. Know the risk profile before you buy.
The Gold /50 and below carry meaningful illiquidity risk. If Holliday's development stalls — another injury, slow stat line, or position change — rare parallels can sit unsold for months. The base BCP-1 and Blue /150 are liquid at almost any price point. The Superfractor and Red /5 are true trophy cards that effectively require a motivated buyer at a specific moment. Size your bets accordingly.
The timing framework for every Holliday position.